#USA #New York #Class Action #Pomerantz Law Firm #Rocket Pharmaceuticals

Class Action Lawsuit Filed Against Rocket Pharmaceuticals

In a significant move for investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), the Pomerantz Law Firm has launched a class action lawsuit following troubling reports about the company's clinical trials. This action raises concerns not just for the firm's operations but also for the integrity of its leadership and their commitment to shareholders.

Pomerantz LLP, a well-known law firm short on its track record in securities and antitrust class litigation, emphasizes the importance of this lawsuit for affected investors. The firm is advising individuals who faced losses after investing in Rocket to contact them regarding this class action. Investors can reach out to Danielle Peyton at [email protected] or by calling 646-581-9980. For convenience, there’s a toll-free number included, 888-4-POMLAW, which potential plaintiffs are encouraged to use.

Allegations of Securities Fraud

The allegations at the heart of this lawsuit revolve around the claims that Rocket Pharmaceuticals and some of its executives may have participated in unlawful business practices, including securities fraud. These concerns have gained traction particularly after a recent press release from the company on May 27, 2025, disclosed a serious adverse event involving a patient participating in a pivotal trial for their gene therapy product, RP-A501, meant to treat Danon disease.

The press release detailed that one of the trial participants developed serious complications, which eventually led to the patient’s death due to an acute systemic infection. This incident prompted Rocket Pharmaceuticals to voluntarily pause the trial and subsequently led to the FDA placing a clinical hold on it for further evaluation.

The announcement bears heavy implications, causing Rocket's stock to plummet dramatically by $3.94 per share, a staggering 62.84% drop on the same day of the news. This has understandably left many investors concerned about the overall integrity of the company's communications and the safety of their investments.

Deadlines and Class Participation

For potential class members, the deadline to register as Lead Plaintiff is approaching fast; those who acquired Rocket’s securities during the Class Period have until August 11, 2025, to step forward. Interested parties can find the complaint online, solidifying its urgency for investors wanting to know more about their rights and options.

Pomerantz has a long history of advocating for the rights of investors suffering from securities fraud and corporate misconduct. Notably, the firm has successfully awarded millions in damages to class members in the past, showcasing its commitment to holding companies accountable for their actions, especially when they lead to financial suffering for shareholders.

Individuals wishing to stay informed or to become part of this class action are urged to review Pomerantz's resources, including accessing the Complaint via www.pomerantzlaw.com, where potential plaintiffs will find additional instructions and information about their legal rights.

About Pomerantz LLP

As one of the leading law firms in securities class actions, Pomerantz has extensive experience in navigating complex cases against corporations. Founded by the esteemed Abraham L. Pomerantz, the firm maintains its legacy by pursuing justice on behalf of victims of corporate misdeeds. With offices across prominent cities such as New York, Chicago, and Los Angeles, Pomerantz remains a pillar in fighting for those seeking redress from the impacts of corporate fraud.

For an ongoing dialogue regarding the developments of this case, affected investors are encouraged to participate actively and explore their avenues for potential recovery.